Henry S. Park, MD, MPH
Associate Professor of Therapeutic RadiologyCards
About
Research
Overview
Population-based Outcomes; Health Services Utilization; Health Disparities; Clinical Trials
Medical Research Interests
Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lung Neoplasms; Radiation; Small Cell Lung Carcinoma
Publications
2024
Evaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma
Husain Z, Rybkin A, Lee V, Young M, Eskander A, Burtness B, Park H. Evaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e759-e760. DOI: 10.1016/j.ijrobp.2024.07.1668.Peer-Reviewed Original ResearchLymphovascular space invasionOral cavity carcinomaOverall survivalIntermediate-riskHigh riskT3/4 diseaseDistant metastasisN stageStandard riskPrediction of distant metastasisGrade 3 tumorsMedian follow-upNational Cancer DatabasePathological risk factorsOral cavity cancerKaplan-Meier methodLog-rank testSubsets of patientsHospital-based cohortClinical trial stratificationHigh-volume hospitalsT3/4 tumorsMedian followSurgical resectionIndividualized treatment selectionAmerican Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy
Amini A, Zaha V, Hamad E, Woodard P, Rimner A, Chang J, Chun S, Donington J, Edelman M, Gubens M, Higgins K, Iyengar P, Juloori A, Movsas B, Ning M, Park H, Rodrigues G, Wolf A, Simone C. American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy. Journal Of Thoracic Oncology 2024, 19: 1654-1667. PMID: 39313150, PMCID: PMC11665043, DOI: 10.1016/j.jtho.2024.09.1433.Peer-Reviewed Original ResearchConceptsCardiac toxicityCardiac comorbiditiesThoracic radiotherapyToxicity preventionAmerican Radium Society Appropriate Use CriteriaAbsence of cardiovascular risk factorsLow riskHigh riskMultidisciplinary consensus guidelinesTreatment-related risksAppropriate Use CriteriaCardiovascular risk factorsVariants of patientsThoracic malignanciesModified Delphi methodologyCardiac substructuresConsensus guidelinesRadiotherapyRisk factorsCardiac imagingComorbiditiesDose exposurePatientsSystematic reviewThoracicAppropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society
Park H, Rimner A, Amini A, Chang J, Chun S, Donington J, Edelman M, Gubens M, Higgins K, Iyengar P, Juloori A, Movsas B, Nemeth Z, Ning M, Rodrigues G, Wolf A, Simone C. Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society. Journal Of Thoracic Oncology 2024, 19: 1640-1653. PMID: 39271016, PMCID: PMC11670059, DOI: 10.1016/j.jtho.2024.09.1386.Peer-Reviewed Original ResearchConceptsAmerican Radium SocietyAppropriate Use CriteriaMultidisciplinary consensus guidelinesProximal tracheobronchial treeConsensus guidelinesRadiation therapyFive-fraction stereotactic body radiation therapyCritical organsManagement of non-small cell lung cancerStereotactic body radiation therapyNon-small cell lung cancerBrachial plexusDefinitive radiation therapyIntensity-modulated radiotherapyStage I NSCLCTracheobronchial treeEarly-stage NSCLCCell lung cancerEnglish medical literatureClinical trial settingHypofractionated radiotherapyInoperable NSCLCUltracentral locationStandard therapyLung tumorsThe Proposed Ninth Edition TNM Classification of Lung Cancer
Detterbeck F, Woodard G, Bader A, Dacic S, Grant M, Park H, Tanoue L. The Proposed Ninth Edition TNM Classification of Lung Cancer. CHEST Journal 2024, 166: 882-895. PMID: 38885896, DOI: 10.1016/j.chest.2024.05.026.Peer-Reviewed Original ResearchAmerican Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer
Rodrigues G, Higgins K, Rimner A, Amini A, Chang J, Chun S, Donington J, Edelman M, Gubens M, Iyengar P, Movsas B, Ning M, Park H, Wolf A, Simone C. American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer. JAMA Oncology 2024, 10: 799-806. PMID: 38602670, PMCID: PMC11665040, DOI: 10.1001/jamaoncol.2024.0294.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAmerican Radium Society Appropriate Use CriteriaAdvanced non-small cell lung cancerAmerican Radium SocietyAppropriate Use CriteriaNon-small cell lung cancerLA-NSCLCUnresectable LA-NSCLCCell lung cancerTreatment of locally advanced non-small cell lung cancerUnresectable locally advanced non-small cell lung cancerLung cancerIntensity-modulated radiotherapy techniqueDecades of clinical trialsPlatinum-based chemoradiationLung cancer radiotherapyEvidence-based consensus documentMultidisciplinary patient careEvidence-based guidelinesRadiotherapy techniquesSalvage therapyFractionation schedulesLocal recurrenceSystemic therapyCancer radiotherapyOpioid prescribing trends and pain scores among adult patients with cancer in a large health system.
Baum L, Soulos P, KC M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Liberatore M, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Journal Of Clinical Oncology 2024, 42: 11059-11059. DOI: 10.1200/jco.2024.42.16_suppl.11059.Peer-Reviewed Original ResearchDocumented painHealth systemOpioid prescribingOpioid prescriptionsOpioid prescribing trendsYale New Haven Health SystemPrescribing trendsMetastatic cancerDocumented pain scoresUS health systemOpioid usePain scoresAdult patientsCalculated predicted probabilitiesFlowsheet dataRetrospective cohort studyRelated harmSolid tumor malignanciesCohort studyCancer painPrescribingContext of cancer treatmentStudy criteriaPainSurgery cohortRadioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically effective doseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failureStereotactic Body Radiotherapy in Locally Advanced Non–Small Cell Lung Cancer—Is This the Future?
Lester-Coll N, Park H. Stereotactic Body Radiotherapy in Locally Advanced Non–Small Cell Lung Cancer—Is This the Future? JAMA Oncology 2024, 10: 360-361. PMID: 38206616, DOI: 10.1001/jamaoncol.2023.5856.Commentaries, Editorials and LettersPatterns of Care for T1 Glottic Squamous Cell Carcinomas from 2004–2020
Malik D, Jacobs D, Fereydooni S, Park H, Mehra S. Patterns of Care for T1 Glottic Squamous Cell Carcinomas from 2004–2020. The Laryngoscope 2024, 134: 3633-3644. PMID: 38411338, DOI: 10.1002/lary.31363.Peer-Reviewed Original ResearchGlottic squamous cell carcinomaT1 glottic squamous cell carcinomaSquamous cell carcinomaDual-modality treatmentOver-treatmentT1a tumorsCell carcinomaTreatment regimensOverall treatment modalityNational Cancer DatabaseRate of surgeryYear of treatmentMultivariate logistic regressionCochran-Armitage testT1b tumorsT1b diseaseCancer DatabaseOver-treatedTreatment modalitiesTreatment patternsAssociated with greater likelihoodSurgeryPatientsTumorLogistic regression
2023
Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex
Jairam V, Soulos P, Madhav K, Gross C, Slotman B, Chiang A, Park H. Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex. Advances In Radiation Oncology 2023, 9: 101413. PMID: 38778819, PMCID: PMC11110031, DOI: 10.1016/j.adro.2023.101413.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerConsolidative thoracic radiotherapyProgression-free survivalSmall cell lung cancerCell lung cancerCREST trialThoracic radiotherapyLung cancerElectronic health record-derived databaseFirst-line systemic therapyStandard first-line treatmentCox proportional hazards regressionFirst-line treatmentNational practice patternsProportional hazards regressionSuperior OSInitial chemotherapyBaseline characteristicsSystemic therapyMale patientsFemale patientsPatient sexHazards regressionSurvival outcomesPractice patterns
Clinical Trials
Current Trials
Prospective Data Registry and Quality of Life Assessment of PatientsUndergoing Radiotherapy With the RefleXion Medical Radiotherapy System (PREMIER Registry)
HIC ID2000034887RolePrincipal InvestigatorPrimary Completion Date04/25/2026Recruiting ParticipantsRAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
HIC ID2000033846RolePrincipal InvestigatorPrimary Completion Date04/30/2027Recruiting ParticipantsMRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
HIC ID2000027403RolePrincipal InvestigatorPrimary Completion Date11/15/2025Recruiting ParticipantsPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
HIC ID2000025868RolePrincipal InvestigatorPrimary Completion Date01/31/2030Recruiting ParticipantsPhase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
HIC ID1604017600RoleSub InvestigatorPrimary Completion Date12/31/2027Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
For Henry S. Park, MD, MPH, building deep and long-lasting relationships with his patients is his favorite part of being a radiation oncologist in the Department of Therapeutic Radiology.
“Even during our first consultation visits, I appreciate how my patients and their families are brave enough to show me the most vulnerable side of themselves,” says Dr. Park. “It's important for me to understand their goals, fears and hopes before I begin to work with them on creating a personalized treatment plan,” he says. “I take this level of trust seriously.”
Dr. Park specializes in treating cancer of the lung and the head and neck. He sees patients at the Smilow Cancer Hospital in New Haven, where he uses advanced radiation techniques like stereotactic body radiation therapy, image-guided radiation therapy, and intensity-modulated radiation therapy to treat patients.
“I try my best to provide high-quality and compassionate care to my patients during this difficult period in their lives,” he says. “And it can be incredibly satisfying.”
As an associate professor of therapeutic radiology and vice chair for clinical research at Yale School of Medicine, he is passionate about being involved in research that may lead to further improvements in cancer care. “My goal for every patient is to use radiation in a customized manner in order to maximize the damage we can do to the cancer and minimize side effects that can affect quality of life,” he says.
Clinical Specialties
Therapeutic Radiology; Thoracic Radiotherapy; Head & Neck Radiotherapy
Fact Sheets
Small Cell Lung Cancer
Learn More on Yale MedicineHead and Neck Cancer
Learn More on Yale MedicineRadiofrequency Ablation (RFA)
Learn More on Yale MedicineThroat Cancer
Learn More on Yale Medicine
Yale Medicine News
News & Links
News
- November 14, 2024
Understanding Lung Cancer: A Conference to Raise Awareness and Offer Hope to Those Impacted by Lung Cancer
- September 05, 2024Source: Yale New Haven Hospital
Smilow announces first administration of unprecedented radiotherapy treatment
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
- March 18, 2024
New YSM Colleges Enhance Community and Mentorship
Get In Touch
Contacts
Email
Academic Office Number
Appointment Number
Clinic Fax Number
Locations
Smilow Cancer Hospital at Yale New Haven
Academic Office
35 Park Street, Rm Lower Level 513
New Haven, CT 06511
Business Office
203.200.2659Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.